Fujifilm Diosynth Biotechnologies announced a 10-year, $3 billion contract with Regeneron Pharmaceuticals Inc. to manufacture biologic medicines in the U.S.
Introducing a New Manufacturing Facility
The agreement states that Fujifilm Diosynth Biotechnologies will make the medicines at its biopharmaceutical manufacturing facility in Holly Springs, North Carolina. The company plans to start production once the site becomes operational later this year.
Fujifilm Diosynth Biotechnologies’ North Carolina facility supports the company’s kojoX interconnected manufacturing network, which applies a modular framework with standardized processes, procedures, and equipment across all locations.
$7B in Upcoming Investments
The contract with Regeneron Pharmaceuticals comes as Fujifilm Diosynth Biotechnologies expects to increase capacity through $7 billion in expansion projects across the U.S. and Europe over the next few years.
Creating 1,400 Jobs
Fujifilm Diosynth Biotechnologies previously invested $4 billion to build biopharmaceutical manufacturing sites, develop life science capabilities, and expand its technical workforce. The company said these efforts helped generate 500 jobs, contributing to its goal of adding 1,400 new positions in North Carolina by 2031.
Fujifilm Diosynth Biotechnologies specializes in developing and producing biopharmaceuticals through host/virus, mammalian, and microbial systems. The company employs more than 4,800 workers.
Image credit: murat photographer/Shutterstock
